TrialBone marrow transplantation2015

Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.

P Gimsing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.